Cerebrovascular DiseaseNCT05491980
Florida Cerebrovascular Disease Biorepository and Genomics Center
An observational study of Cerebrovascular Disease and Ischemic Stroke, run by Mayo Clinic at 1 site in United States.
Trial summary
The purpose of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida, which will include collecting medical history information and blood from subjects affected by cerebrovascular disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cerebrovascular Disease, Ischemic Stroke, Transient Ischemic Attack
- How many people
- 72 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Aug 2022to Jun 2030
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subjects identified with a history of cerebrovascular disease will be recruited from both the in-patient and outpatient services at Mayo Clinic Florida.
Who may be able to join
- Affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid hemorrhage, leukoaraiosis, arteriovenous fistula, reversible cerebral vasoconstriction syndrome (RCVS), and CADASIL.
Who cannot join
- All patients with the following known or suspected virulent microorganisms causing an active or latent infection will be excluded from the study:
- Human immunodeficiency virus (HIV);
- Any viral hepatitis;
- West Nile virus (WNV);
- Influenza virus;
- Tuberculosis (TB);
Show all 9Show fewer
- Any bacteremia;
- Any fungemia;
- Any prionopathy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Creating a Florida Cerebrovascular Disease Biorepository and Genomics Center
The purpose of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida, which will include collecting medical history information and blood from subjects affected by cerebrovascular disease. The information and blood samples collected may be used in future research for the study of cerebrovascular disease and to learn about, prevent or treat other health problems.
- Conditions
- Cerebrovascular Disease, Ischemic Stroke, Transient Ischemic Attack, Intracerebral Hemorrhage, Aneurysmal Subarachnoid Hemorrhage, Vascular Dementia
- Medical subject headings
- Cerebrovascular Disorders, Ischemic Stroke, Ischemic Attack, Transient, Cerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Hypoxia-Ischemia, Brain, Intracranial Thrombosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Stroke or TIA at 12 months
Number of participants to experience new diagnosis of TIA or stroke.
Measured: 1 year
Secondary outcomes (1)
Modified Rankin Scale
Measure of overall functional status
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2022
- Study start2 Aug 2022
- Primary completionJun 2030 (estimated)
- Study completionJun 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebrovascular DiseaseStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 72 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, James F. Meschia, Mayo Clinic
- Investigators
- James Meschia, MD, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05491980
- Sponsor's protocol ID
- 22-002667
- Status last verified
- Jul 2026
- First submitted
- 5 Aug 2022
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No